NOTCH1 and B-cell chronic lymphocytic leukemia: Assessment of the clinical value of NOTCH1 mutations in the CLL8 trial, comparing FCR with FC in first line CLL therapy, has demonstrated that NOTCH1-mutated patients may not benefit from the addition of rituximab to the FC backbone [24].